Farrow joined GBT in April 2016 as chief financial officer with expertise in
leading finance, risk management and investor relations for several public
biotech companies as they evolved from discovery and development to commercial
stage. Mr. Farrow previously served as chief financial officer of ZS Pharma,
Inc., a biopharmaceutical company acquired by AstraZeneca. Prior to ZS Pharma,
he served as chief financial officer at Hyperion Therapeutics, Inc., where he
led the company’s initial public offering and follow-on offering and was part
of the team responsible for the successful regulatory approval and commercial
launch of RAVICTI® for the treatment of urea cycle disorders. He
previously served as vice president of finance at Evotec AG, a drug discovery
and development company. Prior to Evotec, Mr. Farrow served as vice president
of finance and chief accounting officer at Renovis, Inc., a drug discovery and
development company acquired by Evotec AG. Earlier in his career, Mr. Farrow
worked in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business
administration with a concentration in corporate finance from California State
University at Fullerton. He is a certified public accountant (inactive).
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
You are now leaving the Global Blood Therapeutics website
You are currently leaving our site. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Global Blood Therapeutics. Are you sure you want to proceed?